Need help finding what you are looking for?
Contact Us
PUBLISHER: Inkwood Research | PRODUCT CODE: 1142625
PUBLISHER: Inkwood Research | PRODUCT CODE: 1142625
North America Cell Therapy Market Forecast 2022-2030
PUBLISHED:
PAGES: 145 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
KEY FINDINGS
The North America cell therapy market is set to project a CAGR of 14.13% during the forecast period, 2022-2030. The presence of companies like Kolon TissueGene, NuVasive Inc, Bristol-Myers Squibb Company, Gilead Sciences Inc, Vericel Corporation, etc., majorly contributes to market growth. However, the market growth is restrained by stringent regulations.
MARKET INSIGHTS
Canada and the United States are assessed for the North America cell therapy market growth analysis. In Canada, investments and funding by the government are targeted at enhancing the country's stem cell research ecosystem. Also, several stem cell-related clinical trials are underway in the country. In addition, the Canadian Stem Cell Foundation has established a Canadian Stem Cell Strategy and Action Plan for making Canada lucrative for more high-quality stem cell clinical trials.
Further, the presence of centers and institutions like the Centre for Commercialization of Regenerative Medicine (CCRM), the Ontario Institute for Regenerative Medicine, and the Ontario Stem Cell Institute, active in regenerative medicine and stem cells, is beneficial to market growth. Such developments are projected to increase growth opportunities.
COMPETITIVE INSIGHTS
Some of the key firms operating in the market include: Anterogen Co Ltd, JCR Pharmaceuticals Co Ltd, Bristol Myers Squibb Company, etc.
Our report offerings include:
- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Product Code: 48747
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
- 1.1. STUDY OBJECTIVES
- 1.2. SCOPE OF STUDY
- 1.3. METHODOLOGY
- 1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
- 2.1. MARKET SIZE & ESTIMATES
- 2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
- 3.1. KEY DRIVERS
- 3.1.1. INCREASING CELLULAR THERAPY CLINICAL TRIALS
- 3.1.2. GROWTH OF REGENERATIVE MEDICINE
- 3.1.3. HIGH PREVALENCE OF CHRONIC DISEASES
- 3.2. KEY RESTRAINTS
- 3.2.1. INCREASING SKILLS GAP
- 3.2.2. HIGH COSTS
4. KEY ANALYTICS
- 4.1. IMPACT OF COVID-19 ON CELL THERAPY MARKET
- 4.2. KEY MARKET TRENDS
- 4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
- 4.4. REGULATORY FRAMEWORK
- 4.5. OPPORTUNITY MATRIX
- 4.6. VENDOR LANDSCAPE
5. MARKET BY CELL TYPE
- 5.1. STEM CELL
- 5.1.1. BONE MARROW
- 5.1.2. BLOOD
- 5.1.3. UMBILICAL CORD-DERIVED STEM CELL
- 5.1.4. ADIPOSE-DERIVED STEM CELL
- 5.1.5. OTHERS
- 5.2. NON-STEM CELL
6. MARKET BY THERAPY TYPE
- 6.1. AUTOLOGOUS
- 6.2. ALLOGENEIC
7. MARKET BY THERAPEUTIC APPLICATION
- 7.1. MALIGNANCIES
- 7.2. MUSCULOSKELETAL DISORDERS
- 7.3. AUTOIMMUNE DISORDERS
- 7.4. DERMATOLOGY
- 7.5. OTHER APPLICATIONS
8. MARKET BY END-USER
- 8.1. HOSPITALS & CLINICS
- 8.2. ACADEMIC & RESEARCH INSTITUTES
9. GEOGRAPHICAL ANALYSIS
- 9.1. NORTH AMERICA
- 9.1.1. MARKET SIZE & ESTIMATES
- 9.1.2. KEY DRIVERS
- 9.1.3. KEY CHALLENGES
- 9.1.4. KEY PLAYERS
- 9.1.5. COUNTRY ANALYSIS
- 9.1.5.1. UNITED STATES
- 9.1.5.2. CANADA
10. COMPETITIVE LANDSCAPE
- 10.1. KEY STRATEGIC DEVELOPMENTS
- 10.1.1. MERGERS & ACQUISITIONS
- 10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 10.1.3. PARTNERSHIPS & AGREEMENTS
- 10.1.4. BUSINESS EXPANSIONS
- 10.2. COMPANY PROFILES
- 10.2.1. ANTEROGEN CO LTD
- 10.2.2. BRISTOL MYERS SQUIBB COMPANY
- 10.2.3. CELLS FOR CELLS SA
- 10.2.4. GILEAD SCIENCES INC
- 10.2.5. JCR PHARMACEUTICALS CO LTD
- 10.2.6. KOLON TISSUEGENE INC
- 10.2.7. MEDIPOST CO LTD
- 10.2.8. MESOBLAST LIMITED
- 10.2.9. NUVASIVE INC
- 10.2.10. SMITH & NEPHEW PLC
- 10.2.11. STEMEDICA CELL TECHNOLOGIES INC
- 10.2.12. VERICEL CORPORATION
Product Code: 48747
LIST OF TABLES
- TABLE 1: MARKET SNAPSHOT - CELL THERAPY
- TABLE 2: REGULATORY FRAMEWORK
- TABLE 3: NORTH AMERICA CELL THERAPY MARKET, BY CELL TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 4: NORTH AMERICA CELL THERAPY MARKET, BY CELL TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 5: NORTH AMERICA CELL THERAPY MARKET, BY STEM CELL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 6: NORTH AMERICA CELL THERAPY MARKET, BY STEM CELL, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 7: NORTH AMERICA CELL THERAPY MARKET, BY THERAPY TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 8: NORTH AMERICA CELL THERAPY MARKET, BY THERAPY TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 9: NORTH AMERICA CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 10: NORTH AMERICA CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 11: NORTH AMERICA CELL THERAPY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 12: NORTH AMERICA CELL THERAPY MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 13: NORTH AMERICA CELL THERAPY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 14: NORTH AMERICA CELL THERAPY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 15: KEY PLAYERS IN NORTH AMERICA CELL THERAPY MARKET
- TABLE 16: LIST FDA-APPROVED CELL THERAPY PRODUCTS
- TABLE 17: LIST OF MERGERS & ACQUISITIONS
- TABLE 18: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
- TABLE 19: LIST OF PARTNERSHIPS & AGREEMENTS
- TABLE 20: LIST OF BUSINESS EXPANSIONS
LIST OF FIGURES
- FIGURE 1: KEY MARKET TRENDS
- FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
- FIGURE 3: OPPORTUNITY MATRIX
- FIGURE 4: VENDOR LANDSCAPE
- FIGURE 5: NORTH AMERICA CELL THERAPY MARKET, GROWTH POTENTIAL, BY CELL TYPE, IN 2021
- FIGURE 6: NORTH AMERICA CELL THERAPY MARKET, BY STEM CELL, 2022-2030 (IN $ MILLION)
- FIGURE 7: NORTH AMERICA CELL THERAPY MARKET, GROWTH POTENTIAL, BY STEM CELL, IN 2021
- FIGURE 8: NORTH AMERICA CELL THERAPY MARKET, BY BONE MARROW, 2022-2030 (IN $ MILLION)
- FIGURE 9: NORTH AMERICA CELL THERAPY MARKET, BY BLOOD, 2022-2030 (IN $ MILLION)
- FIGURE 10: NORTH AMERICA CELL THERAPY MARKET, BY UMBILICAL CORD-DERIVED STEM CELL, 2022-2030 (IN $ MILLION)
- FIGURE 11: NORTH AMERICA CELL THERAPY MARKET, BY ADIPOSE-DERIVED STEM CELL, 2022-2030 (IN $ MILLION)
- FIGURE 12: NORTH AMERICA CELL THERAPY MARKET, BY OTHERS, 2022-2030 (IN $ MILLION)
- FIGURE 13: NORTH AMERICA CELL THERAPY MARKET, BY NON-STEM CELL, 2022-2030 (IN $ MILLION)
- FIGURE 14: NORTH AMERICA CELL THERAPY MARKET, GROWTH POTENTIAL, BY THERAPY TYPE, IN 2021
- FIGURE 15: NORTH AMERICA CELL THERAPY MARKET, BY AUTOLOGOUS, 2022-2030 (IN $ MILLION)
- FIGURE 16: NORTH AMERICA CELL THERAPY MARKET, BY ALLOGENEIC, 2022-2030 (IN $ MILLION)
- FIGURE 17: NORTH AMERICA CELL THERAPY MARKET, GROWTH POTENTIAL, BY THERAPEUTIC APPLICATION, IN 2021
- FIGURE 18: NORTH AMERICA CELL THERAPY MARKET, BY MALIGNANCIES, 2022-2030 (IN $ MILLION)
- FIGURE 19: NORTH AMERICA CELL THERAPY MARKET, BY MUSCULOSKELETAL DISORDERS, 2022-2030 (IN $ MILLION)
- FIGURE 20: NORTH AMERICA CELL THERAPY MARKET, BY AUTOIMMUNE DISORDERS, 2022-2030 (IN $ MILLION)
- FIGURE 21: NORTH AMERICA CELL THERAPY MARKET, BY DERMATOLOGY, 2022-2030 (IN $ MILLION)
- FIGURE 22: NORTH AMERICA CELL THERAPY MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)
- FIGURE 23: NORTH AMERICA CELL THERAPY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
- FIGURE 24: NORTH AMERICA CELL THERAPY MARKET, BY HOSPITALS & CLINICS, 2022-2030 (IN $ MILLION)
- FIGURE 25: NORTH AMERICA CELL THERAPY MARKET, BY ACADEMIC & RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)
- FIGURE 26: NORTH AMERICA CELL THERAPY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
- FIGURE 27: UNITED STATES CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
- FIGURE 28: CANADA CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.